|
|
The purpose of the RCC is to facilitate the performance of high quality collaborative research in women's health among the National Centers of Excellence in Women's Health and the National Community Centers of Excellence in Women's Health. Together, the National Centers of Excellence in Women's Health (CoE) and National Community Centers of Excellence in Women's Health (CCOE) serve a wide variety of socio-economically, ethnically and racially diverse populations of women located throughout the U.S. The Centers have research interests and expertise in a broad variety of areas including health services research, translational research, behavioral research, and clinical research, including clinical trials and basic research.
The RCC is currently coordinating the following clinical research studies:
Pharmacokinetics and Pharmacodynamics of Selected Antibiotics During Pregnancy
The Research Coordinating Center's first undertaking and one source of its original funding is the multi-site research project, Pharmacokinetics and Pharmacodynamics of Selected Antibiotics During Pregnancy. Five National Centers of Excellence are participating in this prospective, open-label study; University of Wisconsin-Madison, University of Illinois - Chicago, University of Michigan, Harvard University and Boston University. The nation’s recent threats of bioterrorism have heightened the need for further information regarding dosing and safety data of anti-infective agents used to treat medical conditions resulting from such an attack. The pharmacokinetic and pharmacodynamic data of many anti-infective agents in pregnant and lactating women is lacking so that optimization of dosage regimens cannot be evaluated. The purpose of this project is to support research conducted by the National Centers of Excellence in Women’s Health to assess changes in the pharmacokinetics and pharmacodynamics of certain prescription drugs in pregnant and lactating women; and/or to study fetal effects of pharmaceutical treatment of the mother. Information collected in the study may be incorporated into the drug label and public health advisories. For more information, contact lw3@clinicaltrials.wisc.edu.
The RCC is currently participating in the following clinical research studies:
ExCel Breast Cancer Prevention Clinical Trial
[http://www.excelstudy.com/index.html/] The ExCel research study is a phase III breast cancer prevention clinical trial. It is a new and important international clinical trial designed to determine whether a special type of medication can prevent breast cancer in healthy postmenopausal women who are at increased risk for developing breast cancer.
Women's Health Initiative (WHI)
UW Madison was one of 40 national sites to participate in the landmark Women's Health Initiative (WHI) study. The study was the largest, most definitive long-term study of postmenopausal women's health ever undertaken in the US. Launched in 1992, it was designed to study the risks and benefits of strategies that could potentially reduce the incidence of heart disease, breast and colorectal cancer and fractures (the major causes of death, disability and impaired quality of life in older women in the US). 161, 809 postmenopausal women, aged 50-79 enrolled in the study nationally. The Madison WHI Clinical Center enrolled 3530 women. The core study has been completed; however, substudies are currently being conducted with the same group of recruited women. For more information, visit the Madison WHI at:
| ||||||||
